FOLH1 and Nephropathy: However, there remains clinical uncertainty regarding the safe limits of dose to the kidneys which are a key at-risk organ with PSMA-targeted RLT, with decline in renal function and histopathologically-confirmed nephropathy having been documented in patients undergoing 177Lu-labelled PSMA RLT [14, 15, 16].